The FDA approved Pacira BioSciences' supplemental new drug application to expand the indication of Exparel, its injectable bupivacaine liposome suspension treatment to cover pediatric patients aged 6 years and older. The drug is used for post-surgical non-opioid pain control.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.